STUDY QUESTION: Is there molecular evidence for a link between endometriosis and endometriosis-associated ovarian cancers (EAOC)?
Introduction
Endometriosis is a common, oestrogen-dependent, gynaecological disorder reported in~10% of women in reproductive age and associated with chronic pelvic pain and infertility. Endometriosis is generally considered a benign condition, although these lesions sometimes exhibit aberrant characteristics such as enhanced growth, neo-angiogenesis, local deep invasion and cell migration (Munksgaard and Blaakaer, 2012) .
A small group of women with endometriosis (~0.7-2.5%) has an increased risk for developing certain ovarian cancer subtypes; namely, clear cell, endometrioid invasive and low-grade serous ovarian cancers (Pearce et al., 2012; Gadducci et al., 2014) . Likewise, pooled metaanalysis from several epidemiological studies on the above types of endometriosis-associated ovarian cancer (EAOC) show an increased risk (OR: 1.32-1.92) for women with endometriosis (Kryczek et al., 2012) . A variety of cancer-related somatic mutations have been previously identified in endometrioma, resulting in silencing of tumour suppressor genes TP53 (Sainz de la Cuesta et al., 2004) , PTEN and ARID1A; activation of oncogenes KRAS, PIK3CA, CTNNB1 (Gadducci et al., 2014) and PPP2R1A (Anglesio et al., 2017) and downregulation of BCL2 (Nezhat et al., 2002) . Nevertheless, the cellular and molecular changes that precede the above aberrations, and the potential risk towards EAOC, are not fully understood (Pollacco et al., 2012) .
The stem cell theory for development of endometriosis suggests that endometrial stem cells/progenitors (SC) with altered molecular properties reflux via retrograde menstruation into the abdominal cavity where they adhere and form ectopic lesions. The presence of SC in menstrual blood (Musina et al., 2008) , peritoneal fluid (Dorien et al., 2017) and endometriotic lesions (Gargett et al., 2014) in women with endometriosis has engaged researchers to explore the molecular link between actively regenerating endometrial SC and endometriosis (Cheng et al., 2017) . Nevertheless, the direct evidence for the role of SC in endometriosis or malignant transformation of endometrial cells, which might lead towards the onset of EAOC, is still missing.
Herein, we hypothesize that a subpopulation of multipotent SC within endometrioma or endometrium of certain endometriosis patients may undergo aberrant alterations within cancer-associated genes, which may in turn increase the future risk of EAOC. Therefore, we aimed to screen the expression levels of a selected panel of endometrial or ovarian cancer-associated gene markers in isolated endometrial multipotent stem cells/progenitors as well as in a separate cohort of whole endometrial and endometrioma tissue biopsies.
Materials and Methods

Patient data
Endometrial samples (P-En, n = 37) and their paired-endometriotic lesions (Endo, n = 30) were collected from endometriosis patients during laparoscopic surgery from both Karolinska University Hospital, Sweden and Tartu University Hospital's Women's clinic, Estonia. All the patients recruited had not received any hormonal medications for at least 3 months before surgery and were verified by a pathologist for indications of moderate to severe endometriosis (stages III-IV, classified according to ASRM guidelines (American Society for Reproductive Medicine: Revised classification of endometriosis, 1997)). The patients' median age was 33.9 ± 5.6 years (years ± SD) and BMI was 22.29 ± 3.51 kg/m 2 .
Endometrial biopsies (H-En) were collected from healthy women as controls at Karolinska University Hospital for both isolating SC (secretory phase, n = 14) as well as for whole tissue protein analysis (proliferative phase, n = 5). All above volunteers were within their fertile age (≤40 years), with normal BMI (within a range of 19-25), regular menstruation, had at least one live-born child and were clinically examined for the absence of hormonal diseases or uterine pathologies such as endometriosis, polycystic ovary syndrome and/or previous infertility records. In addition, control ovarian tissue biopsies (n = 4) were obtained from Tartu University Hospital's Women's clinic for evaluation of ovarian specific markers.
Ethical approval
The regional ethics committee at Stockholm, Sweden and at Tartu, Estonia approved the study. Written informed consent was obtained from all enrolled participants.
Endometrial stem cell isolation
Endometrial cell isolation from both patients and control samples (P-En, Endo and H-En; SC cohort) were performed according to our standard protocol, as previously described (Lalitkumar et al., 2013) . Briefly, endometrial tissues were homogenized, treated in sequential steps of pancreatin-0.05% trypsin enzymatic solution, collagenase 4 (0.1 U/ml) and DNaseI (16 μg/ml) solution in Ca 2+ /Mg 2+ -free PBS (Gibco ® Thermo
Fisher Scientific, Sweden) and incubated for 30 min at each step. However, thick endometriotic fibrous tissue (Endo) weighing~200-300 mg required an altered enzymatic digestion mixture containing collagenase/dispase (Collagenase: 0.1 U/ml, Dispase: 0.8 U/ml, Roche Diagnostics) and DNaseI (16 μg/ml) with longer incubation time (60-90 min). Cell suspensions from both procedures were then expanded in vitro for two generations. (BD Biosciences, USA) and 4′,6-diamidino-2-phenylindole (DAPI) using BD LSRII flow cytometry (BD Biosciences, USA). Ovarian (SKOV3) and endometrial (Ishikawa) cancer lines were used as positive control. Cell distributions were enumerated as percentages in different phases of the cell cycle using pseudo-dot plots generated by flow cytometry.
3D-spheroid SC + cultures
To assess self-renewal capacity, pluripotency and de-differentiation potential, expanded monolayer SC + cells (4000 cells/cm 2 ) from H-EnSC, P-EnSC and EndoSC groups were able to form suspension 3D-spheroids when plated on to ultra-low attachment six-well plates (Corning ® Thermo
Fischer Scientific Inc., USA) and cultured with sphere enrichment medium containing DMEM/F12, growth factors EGF, bFGF (10 ng/ml each, Invitrogen ® Thermo Fisher Scientific, Sweden), B27 supplement and Insulin-Transferrin-Selenium (Gibco ® Thermo Fisher Scientific, Sweden), as well as 2 nM progesterone (Sigma Aldrich, USA). 3D-Spheroid suspensions were allowed to grow up to a size larger than 50 μm and harvested 5-7 days after the onset of culture. Spheroids were dissociated, single cells were reseeded with the above conditions and later harvested for downstream applications.
Differential gene expression and data analysis
To evaluate the changes in gene expression at the cellular and, more broadly, tissue level, patients' samples were sub-divided into two independent cohorts: (i) the multipotent stem cell cohort (SC + cohort, pairedendometrium and -endometrioma samples collected at secretory phase, n = 11 and unpaired endometria, n = 7) for cell culture experiments and (ii) whole tissue biopsies from paired-endometrium and -endometrioma (named as Tissue cohort; proliferative phase, n = 19). Table S1 ) and quantified using StepOne Plus real time PCR (Applied Biosystems TM Thermo Fisher Scientific, Sweden).
Fold changes (FC) between the groups were calculated using the formula 2 −ΔCT (P-EnSC or EndoSC) /2 −ΔCT (H-EnSC) in accordance to comparative C T method (Schmittgen and Livak, 2008) . Heat-maps with hierarchical clustering were generated with the Morpheus online tool (Broad Institute Inc.) using gene expression patterns from a panel of genes and applying Euclidean neighbouring distance method. Later, group variability was assessed with multivariate modelling, orthogonal partial least squaresdescriptive analysis (OPLS-DA) using SIMCA 14 software (Umetrics AB, Umea, Sweden).
Flow cytometry analysis
Phenotypic characterization of sorted SC + and SC − fractions were performed using cell surface markers, anti-human antibodies CD44-PE, CD146-PerCP-cy5.5, PDGFRβ/CD140b-PE and SUSD2/W5C5-APC (Biolegend, USA), EPCAM-PE (Miltenyi Biotec, Germany), ABCG2-PerCPcy5.5 (Biolegend, USA), SSEA1-Alexa Fluor 488 (Santa Cruz Biotec.) and CD45-APC (BD Pharmingen, USA). Also, in vitro monolayer SC + cultures and respective 3D-spheroid cultures from H-En, P-En and Endo groups were compared for expression of ALDH1 enzyme by ALDEfluor assay (Stem cell technologies, Canada) and anti-human antibodies CD133-1-APC (Miltenyi Biotec, Germany), CD44-PE (Biolegend, USA) and CD117-PE-cy7
(Biolegend, USA). Percentage expression of these surface markers as well as their co-expression were calculated with respect to total live cells and presented using FlowJo data analysis software (LLC, Oregon).
Confocal imaging
Spheroid SC+ cultures were checked for co-expression of stem cell markers using dual colour immunofluorescence. Spheres were fixed with 4% paraformaldehyde, washed, blocked and permeabilized with 2% BSA in 0.1% Triton. Representative samples from each group were stained with primary antibodies anti-human OCT3/4 antibody (Santa Cruz Biotechnology, USA), CD44v6-Alexa Fluor 488 (Biolegend, USA) and rabbit polyclonal PROM1/CD133 (Biorbyt, UK) overnight at 4°C and later tagged with secondary antibodies, donkey anti-mouse Alexa Fluor 488 (Molecular Probes ® Life technologies) and goat anti-rabbit Abberior ® STAR633 (Abberior). The SKOV3 ovarian cancer line was used as positive control. Images were captured using Zeiss LSM 700 confocal microscopy (Carl Zeiss, Japan).
Automated western blot
Protein levels were studied in both cohorts (SC and Tissue cohorts) along with the positive control MCF7 breast cancer line (kind gift from Johan Hartman, Karolinska Institutet) using automated western blot (Protein Simple, San Jose, CA). Briefly, 0.4 mg/ml of protein from either multipotent SC + or tissue lysates were mixed with fluorescent master-mix (Protein Simple) and loaded into pre-designed Wes assay plates along with primary antibodies, mouse anti-human E-cadherin (MAB1838, R&D systems), ER-alpha/NR3A1 (clone:68118) and ER-beta/NR382 (Clone:733930) (both from Novus Biologicals), beta actin (Cell signalling) and other components as per the manufacturer's instructions. Samples were drawn automatically by Simple Wes machine into pre-designed capillaries and proteins separated by capillary electrophoresis. Detections were made with either streptavidin or secondary anti-mouse-HRP followed by luminol peroxide mix (Protein Simple, USA). Image analysis was performed using Compass software (Protein Simple, USA).
Statistical analysis
GraphPad Prism 6 and 7 softwares (GraphPad Software Inc., USA), were used for statistical analysis and illustrations. Datasets were checked for Gaussian distribution and homogeneity of variance using Shapiro-Wilk's normality test. T-test (paired/unpaired, parametric), Wilcoxon signed T-test (paired, non-parametric) or Mann-Whiteney test (unpaired, nonparametric) were used for comparisons involving two groups, while oneor two-way Anova (paired, parametric) or Kruskal-Wallis test (unpaired, non-parametric) were used for multiple group comparisons. P-values were adjusted for false discovery using the Benjamini, Krieger and Yekutieli method.
Results
Evaluating endometriosis tissues for expression of Mullerian marker
To assess whether the endometrioma samples used in this study are free from ovarian cells, we looked into the gene expression levels between paired-endometrium (P-En) and -endometrioma (Endo) samples from endometriosis women (tissue cohort, n = 16) as well as healthy ovarian tissues (n = 4) for the well-known ovarian tissue marker, anti-Mullerian hormone receptor-II (AMHRII). Previously, AMHRII was reported to be highly expressed in endometriotic tissues compared with endometrium both with and without endometriosis (Carrarelli et al., 2014) . In line with this observation, Endo tissue samples showed significant upregulation compared with P-En (FC: 852.37; P < 0.0001; Fig. 2A ). Interestingly, Endo showed a significantly lower expression level compared with ovarian tissues (FC: 3.36; P < 0.05), thus indicating a unique cellular phenotype for Endo with respect to both P-En and ovarian tissues.
Characterization of multipotent SC + from healthy endometria and patient endometria and endometrioma
Multipotent SC
+ from P-En, Endo and H-En were isolated, after a brief in vitro expansion, using widely-known mesenchymal stem cell markers CD73, CD90 and CD105 suggested by International Society for Cell therapy (Dominici et al., 2006) (Fig. 2B) AMHRII between paired-samples from endometriosis patients (tissue cohort) endometrium (P-En, n = 16) and endometrioma (Endo, n = 16), compared with healthy ovarian tissues (n = 4). (B) Cell isolation strategy for sorting SC from in vitro expanded H-EnSC (n = 14), P-EnSC (n = 18) and EndoSC (n = 11) by flow cell sorter using markers CD73, CD90 and CD105. OCT3/4, SOX2 and NANOG (Fig. 2D-i-iii) , oestrogen receptors ER-α and ER-β (Supplementary Figure S1 .A-i,-ii) and proliferation marker ki67 (Supplementary Figure S1 .B-iii). SC + showed high expression of SOX2 (FC: 4.3 ± 0.33, P < 0.05), NANOG (FC: 1.80 ± 0.83; P < 0.05) and ER-α (FC: 1.8 ± 0.43; P < 0.05) compared with SC − in pooled analysis from both P-En and Endo groups. Also, SC + showed higher colony forming efficiency (SC + 9.3 ± 1.5% and SC − 2.8 ± 0.2%; P < 0.05; Fig. 2E -i,-ii) when seeded at sub-optimally low dilutions (100 cells/ cm 2 ). Subsequently, SC + alone showed mesenchymal multi-lineage potential as they were able to differentiate into adipocytes, osteocytes and chondrocytes (Fig. 2F) . Furthermore, we assessed the proliferation and cell cycle distribution among paired-endometriosis SC + and healthy SC + . DAPI staining revealed the presence of single G1 and G2 peaks, indicating no sign of aneuploidy in any of the sample groups (Supplementary Figure S1B) . Upon BrdU pulse treatment, P-EnSC in comparison with H-EnSC samples showed significant increase in BrdU + cells (S-phase cells) (9.34 ± 6.42% and 4.11 ± 2.04%, P < 0.05, Supplementary Figure S1C , S1D-i). Additionally, within total S-phase, both P-EnSC and EndoSC presented a significant increase of cells in early-S phase in comparison with H-EnSC (P-EnSC: 4.33 ± 2.71%, EndoSC: 4.47 ± 2.56 and H-EnSC: 1.91 ± 1.22%, P < 0.01, Supplementary  Figure S1D -ii).
De-differentiation, stem and ovarian cancer-related markers enriched in certain endometriotic SC 3D-multicellular spheroid technique was adopted to assess markers of pluripotency or de-differentiation potential (OCT3/4, SOX2, NANOG) Figs 3A -i,-ii, 3B-i). Interestingly, H-EnSC and P-EnSC spheroid cultures showed significant gene expression differences for genes OCT3/4 (FC: 1.80 ± 0.76; P < 0.05) and NANOG (FC: 22.12 ± 1.84, P < 0.01) (Fig. 3B) , while H-EnSC and EndoSC spheroids showed a significant difference for gene SOX2 (FC: 13.26 ± 0.84, P < 0.01) and a strong trend for HIF1α (FC: 21.07 ± 4.34; P = 0.055). However, there were no significant differences in ovarian cancerassociated markers between healthy and patient or between paired-patients' groups, assessed by flow cytometric analysis (Fig. 3C) . Further, we investigated protein levels for co-expression of stem cell and ovarian cancer-related markers (OCT3/4 and CD133 as well as CD44v6 and CD133) between H-EnSC, P-EnSC and EndoSC. Surprisingly, one of the endometrioma samples (EndoSC36) showed coexistence for ovarian cancer-associated markers CD44v6, OCT3/4 and CD133 compared with other EndoSC, all H-EnSC and P-EnSC samples (Fig. 3D ).
Gene deregulation in a subset of in vitro expanded endometriosis SC + cultures
Firstly, we explored the intrinsic differences within endometriosis SC + samples by selecting a panel of 42 stem cell and cancer-related genes that were previously reported for their association with endometrial or ovarian cancer (Supplementary Table S1 ), using customized RT-PCR array. A significant downregulation in PTEN, ARID1A and TNFα (P < 0.05) was observed in EndoSC compared with P-EnSC. Alternatively, P-EnSC showed downregulation of ARID1A, BCL2 and ALDH1A1 (P < 0.05) and upregulation of PTEN, TNFα and MMP3 (P < 0.05, Table I ) in comparison with H-EnSC.
Further, we applied a combination of bio-informatics tools such as hierarchical cluster analysis and multivariate OPLS-DA models to explore patient specific gene expression variability between H-EnSC and P-EnSC groups (Fig. 4A-i , B-i) as well as between paired-P-EnSC and -EndoSC groups (Fig. 4A-ii, B -ii). Comparison between P-EnSC and H-EnSC groups revealed clear distinct clusters, attributing to the disease pathophysiology. Moreover, P-EnSC intragroup analysis with multivariate OPLS-DA model identified three high-expression samples (En29, En24 and En36) forming a separate cluster with high gene expression variability (P-EnSC-hi) from other homogenous low-expression samples (P-EnSC-lo). Further, we discriminated differentially expressed genes between the above subgroups and observed upregulation of genes such as MMP3, ERα/ESR1, CDH1/E-cadherin (P < 0.01), TGF-beta, Ki67, ARID1A, KRAS, FOS/USF2 and BMI1 (P < 0.05; Supplementary  Figure S2A-i) . On other hand, three-paired-endometriosis P-EnSC and EndoSC samples (#24 and #36 and #18) showed aberrant gene expression pattern forming a separate cluster (referred as high-expression variability pairs) from rest of the homogenous paired samples (low-expression variability pairs). Further, we searched for discriminating genes between the above two groups by comparing gene expression ratios of EndoSC/P-EnSC and observed upregulation of genes KIT, E-Cadherin, HIF2α and downregulation of NOTCH3, VEGFα, PTEN and ARID1A (P < 0.05; Table II and Supplementary Figure S2A -ii).
Moreover, we compared the gene expression ratio and protein levels of oestrogen receptors -α and β (ESR1, ESR2). We detected aberrant gene expression ratio of ER-β/ER-α in two patients (#24 and #36; Fig. 4C ). However, protein validation revealed higher levels of ER-β in EndoSC-hi (#24) compared with all other samples (Supplementary Figure S2B-i,-ii) . Also, E-cadherin protein fragments were detected in one of the high-variability samples EndoSC36 (Supplementary Figure S2B-iii) .
Validation of aberrant gene expression profile in whole endometriosis tissues
We measured the gene expression of 25 out of 42 pre-selected markers based on the results from SC cohort (Supplementary Table S1 ) and 17 genes were differentially expressed between paired-endometrium (P-En) and -endometrioma (Endo) tissue groups. Intragroup heterogeneity within P-En (blue) and Endo (green) samples was explored using hierarchical heat-map clustering (Fig. 5A ) and OPLS-DA multivariate model analysis (Fig. 5B) . We identified only one endometrioma sample (Endo238) which had a highly-altered gene expression profile,~95% CI. The top deregulated genes in E238 compared with other paired samples are presented in Table III .
Similar to the SC cohort, we observed significant differences in ER-β/ER-α mRNA transcript ratio in whole tissues of P-En and Endo groups (P < 0.0001; Fig. 5C ). In line with gene expression trend, Endo groups showed high ER-β protein levels compared with ER-α, while P-En and H-En both showed moderate levels of ER-α and ER-β (Supplementary Figure S2C-i,-ii) . Conversely, the E-cadherin/N-cadherin gene expression ratio was higher in P-En compared with Endo (P < 0.0001) and E-cadherin protein levels (120 kDa and its cleaved 98 kDa fragment) were also higher in P-En groups (Fig. 5D and Supplementary  Figure S2C-iii) . Interestingly, patient E238 alone showed altered characteristics with equal E-cadherin/N-cadherin gene expression ratios between P-En and Endo samples in contrast to the downregulated pattern observed in other samples. Also, E-cadherin protein fragments (98 kDa) were detected only in E238 patient's endometrioma. and patients' endometrium (P-EnSC, n = 18) and (ii) paired-P-EnSC and -EndoSC of endometriosis patients (n = 11). (B) Scatter plot from multivariate OPLS-DA model for above samples, compared between (i) H-EnSC and P-EnSC and (ii) paired-P-EnSC and -EndoSC in reference to cancer lines (Ishikawa, SKOV3, A2780). (C) Gene expression ratios of ER-β/ER-α compared between H-EnSC (n = 14), P-EnSC−hi (n = 3), P-EnSC−lo (n = 15), EndoSC−hi (n = 3) and EndoSC−lo (n = 8). *P < 0.05; **P < 0.01. 
Discussion
Although several theories have emerged about the biological processes behind malignant transformation of endometrial cells leading into EAOC, we still lack a deeper knowledge of the molecular changes or mechanisms behind disease development. In this study, we investigated one of the most challenging questions that prevail on the aetiology of EAOC: do adult multipotent stem cells/progenitors in endometrioma of higher cancer risk patients contain a subpopulation of cells with a cancer-associated gene signature? For the first time, we report a highly-altered molecular profile in a small subgroup of women with ovarian endometriosis, having overexpression of genes KIT, HIF2α and E-cadherin, altered ER-β/ER-α expression ratio and downregulation of tumour suppressor genes PTEN and ARID1A; and hypothesize that these changes may be potentially relevant to the development of EAOC. We believe that the observed aberrant expression of stemand cancer-associated markers could reflect early molecular events prior to or in parallel with deleterious gene mutations/deletions, which may trigger de-differentiation, and/or alter epithelial versus mesenchymal phenotype in benign endometriotic multipotent SC, leading to increased risk of EAOC. The postulated theory and findings from this study are summarized in Fig. 6 . Previous studies have shown a key role for stem cells/progenitors (SC + ) in aetiology of endometriosis (Cheng et al., 2017) . Although SC have been identified in most of the vascularized tissues throughout the body (Crisan et al., 2008) including endometriosis (Tanaka et al., 2003) , still the composition of cell surface markers in SC within endometrium and endometrioma is not clearly defined. Hence, we opted for widely-reported criteria for mesenchymal stem cells such as ≥95% of the sorted population expressing markers CD73, CD90 and CD105, and ≤2% of the sorted population expressing markers CD14, CD34 and CD45 (Dominici et al., 2006 small fraction among them still expressed early epithelial markers such as EPCAM + and W5C5 + SSEA1 + . This was in concurrence with a previous report where a small fraction of W5C5 + endometrial stromal cells expressed epithelial cell adhesion molecule (Masuda et al., 2012) . Therefore, we suggest that sorted SC + in our study may have some already characterized and some uncharacterized surface markers and include minor progenitor subsets displaying epithelial markers. Epidemiological data show 0.7-2.5% of endometriosis patients have a potential risk for EAOC (Gadducci et al., 2014) . To investigate if endometriosis patients undergo alterations in key cellular pathways facilitating the onset of EAOC, we checked a panel of previously reported 42 genes associated with stem cell dysfunction or cancerrelated properties on SC + populations. Although a majority of our SC + samples expressed the studied markers at moderate expression levels, our inter-and intragroup analyses identified patients (#36, #24 and #18) with higher gene expression profile, in comparison with the eight other paired samples. To further strengthen these findings, we also validated a selective panel of significant genes in another independent cohort of 19 paired tissue samples and identified one endometrioma (E238) exclusively showing highly-altered profile with more than 95% CI for the studied molecular markers. Remarkably, endometrioma of the above four high-variability samples (#24, #36, #18 from SC cohort and #E238 from tissue cohort) compared with other low variability samples showed upregulation of genes relevant to potential risk for cancer, KIT, HIF2α, E-cadherin ( Sato et al., 2000) and ARID1A (Wiegand et al., 2010) were previously identified as part of early events towards the onset of EAOC. Ecadherin, is generally not considered to be directly associated with cancer progression; however, recent studies have demonstrated that Ecadherin upregulation may have relevance with mesenchymal-toepithelial transitions during metastatic seeding of primary cancers (Wells et al., 2008) . Furthermore, the above high-variability endometrioma samples exclusively displayed aberrant ER-β mRNA and protein levels. This key observation is in concordance with previous reports on a tumour suppressive role of ER-β, controlling the onset of ovarian cancer (Pujol et al., 1998; Lazennec, 2006) . Hence, we postulate that the high-variability group of endometriotic SC might be involved in dedifferentiation of mesenchymal SC into a more epithelial stem-like phenotype, leading to the increased risk for development of epithelial ovarian cancer.
As only a few studied SC and whole tissue samples showed significant alterations in gene expression signatures, the clinical history of these patients were also carefully inspected. Patient E238 had been reported previously with melanoma. Though it is a non-gynaecological cancer, there are convincing epidemiological and clinical reports in favour of an association between endometriosis and the elevated risk for melanoma (Farland et al., 2017) ; however, a molecular link between the two diseases is currently unknown. We acknowledge ns P > 0.05; *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001; ****P ≤ 0.0001.
that the observed molecular signatures indicating a potential risk of EAOC should be validated among a larger cohort of endometriosis patients. Despite having stringent patient inclusion criteria, certain limitations need to be considered in the present study. Firstly, by adopting a preselected panel of genes, we might have missed several other key differentially regulated genes associated with EAOC. However, we believe that above approach is advantageous compared to whole transcriptome analysis as it would specifically focus on smaller gene expression changes for the above pre-selected genes leading to EAOC (Pollacco et al., 2012) . Secondly, women displaying highly-altered gene signatures observed among potential risk patients with endometriosis may or may not have EAOC later in life and thus our findings need to be confirmed on archived tissue samples from women with endometriosis who later in life developed ovarian cancer. Thirdly, cell culture per se may have some impact on the gene expression levels. However, multipotent SC + from endometrioma and endometrium were isolated and handled exactly in the same way for the entire cohort, thus the alteration observed in gene expression levels in some patients' samples likely present true alterations.
In conclusion, we observed an aberrant gene expression profile in a small subset of women with ovarian endometriosis, which could be a part of preceding steps towards malignant conversion of endometriotic cells to EAOC phenotype. The information gained from this study, with further confirmation, may help us to screen women with higher risk for developing EAOC, thus providing an opportunity to take prophylactic measures to prevent a life-threatening disease.
Supplementary data
Supplementary data are available at Human Reproduction online.
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